title: Randomized phase III study of bevacizumab plus FOLFIRI and bevacizumab plus mFOLFOX6 as first-line treatment for patients with metastatic colorectal cancer (WJOG4407G).
abstract: FOLFIRI and FOLFOX have shown equivalent efficacy for metastatic colorectal cancer (mCRC), but their comparative effectiveness is unknown when combined with bevacizumab.
  
  
  
  WJOG4407G was a randomized, open-label, phase III trial conducted in Japan. Patients with previously untreated mCRC were randomized 1:1 to receive either FOLFIRI plus bevacizumab (FOLFIRI + Bev) or mFOLFOX6 plus bevacizumab (mFOLFOX6 + Bev), stratified by institution, adjuvant chemotherapy, and liver-limited disease. The primary end point was non-inferiority of FOLFIRI + Bev to mFOLFOX6 + Bev in progression-free survival (PFS), with an expected hazard ratio (HR) of 0.9 and non-inferiority margin of 1.25 (power 0.85, one-sided α-error 0.025). The secondary end points were response rate (RR), overall survival (OS), safety, and quality of life (QoL) during 18 months. This trial is registered to the University Hospital Medical Information Network, number UMIN000001396.
  
  
  
  Among 402 patients enrolled from September 2008 to January 2012, 395 patients were eligible for efficacy analysis. The median PFS for FOLFIRI + Bev (n = 197) and mFOLFOX6 + Bev (n = 198) were 12.1 and 10.7 months, respectively [HR, 0.905; 95% confidence interval (CI) 0.723-1.133; P = 0.003 for non-inferiority]. The median OS for FOLFIRI + Bev and mFOLFOX6 + Bev were 31.4 and 30.1 months, respectively (HR, 0.990; 95% CI 0.785-1.249). The best overall RRs were 64% for FOLFIRI + Bev and 62% for mFOLFOX6 + Bev. The common grade 3 or higher adverse events were leukopenia (11% in FOLFIRI + Bev/5% in mFOLFOX6 + Bev), neutropenia (46%/35%), diarrhea (9%/5%), febrile neutropenia (5%/2%), peripheral neuropathy (0%/22%), and venous thromboembolism (6%/2%). The QoL assessed by FACT-C (TOI-PFC) and FACT/GOG-Ntx was favorable for FOLFIRI + Bev during 18 months.
  
  
  
  FOLFIRI plus bevacizumab was non-inferior for PFS, compared with mFOLFOX6 plus bevacizumab, as the first-line systemic treatment for mCRC.
  
  
  
  UMIN000001396.
authors.affiliation: Division of Gastrointestinal Oncology, Shizuoka Cancer Center, Shizuoka k.yamazaki@scchr.jp.
authors.forename: K
authors.initials: K
authors.lastname: Yamazaki
authors.affiliation: Department of Clinical Oncology, Jichi Medical University, Shimotsuke.
authors.forename: M
authors.initials: M
authors.lastname: Nagase
authors.affiliation: Department of Surgery, Osaka General Medical Center, Osaka.
authors.forename: H
authors.initials: H
authors.lastname: Tamagawa
authors.affiliation: Department of Medical Oncology, Kinki University Faculty of Medicine, Higashiosaka.
authors.forename: S
authors.initials: S
authors.lastname: Ueda
authors.affiliation: Department of Medical Oncology, Nara Hospital Kinki University Faculty of Medicine, Ikoma.
authors.forename: T
authors.initials: T
authors.lastname: Tamura
authors.affiliation: Department of Surgery, Suita Municipal Hospital, Suita.
authors.forename: K
authors.initials: K
authors.lastname: Murata
authors.affiliation: Department of Clinical Oncology, St Marianna University School of Medicine, Kawasaki.
authors.forename: T
authors.initials: T
authors.lastname: Eguchi Nakajima
authors.affiliation: Department of Comprehensive Clinical Oncology, Kyushu University Faculty of Medical Sciences, Fukuoka.
authors.forename: E
authors.initials: E
authors.lastname: Baba
authors.affiliation: Department of Gastroenterological Oncology, Hyogo Cancer Center, Akashi.
authors.forename: M
authors.initials: M
authors.lastname: Tsuda
authors.affiliation: Division of Gastroenterology, University of Tsukuba, Tsukuba.
authors.forename: T
authors.initials: T
authors.lastname: Moriwaki
authors.affiliation: Department of Gastrointestinal and Medical Oncology, National Hospital Organization Kyushu Cancer Center, Fukuoka.
authors.forename: T
authors.initials: T
authors.lastname: Esaki
authors.affiliation: Department of Medical Oncology, Tonan Hospital, Sapporo.
authors.forename: Y
authors.initials: Y
authors.lastname: Tsuji
authors.affiliation: Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya.
authors.forename: K
authors.initials: K
authors.lastname: Muro
authors.affiliation: Clinical Oncology, Osaka City General Hospital, Osaka.
authors.forename: K
authors.initials: K
authors.lastname: Taira
authors.affiliation: Division of Gastroenterology, Chiba Cancer Center, Chiba.
authors.forename: T
authors.initials: T
authors.lastname: Denda
authors.affiliation: Department of Surgery, Sakai Hospital Kinki University Faculty of Medicine, Sakai.
authors.forename: S
authors.initials: S
authors.lastname: Funai
authors.affiliation: Division of Clinical Oncology, Hiroshima Prefectural Hospital, Hiroshima.
authors.forename: K
authors.initials: K
authors.lastname: Shinozaki
authors.affiliation: Department of Gastroenterology and Hepatology, Okayama Medical Center, Okayama.
authors.forename: H
authors.initials: H
authors.lastname: Yamashita
authors.affiliation: Department of Clinical Oncology, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka.
authors.forename: N
authors.initials: N
authors.lastname: Sugimoto
authors.affiliation: Division of Gastroenterology, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe.
authors.forename: T
authors.initials: T
authors.lastname: Okuno
authors.affiliation: Department of Gastrointestinal Medical Oncology, National Hospital Organization Shikoku Cancer Center, Matuyama.
authors.forename: T
authors.initials: T
authors.lastname: Nishina
authors.affiliation: Department of Surgery, Hyogo Prefectural Awaji Medical Center, Sumoto.
authors.forename: M
authors.initials: M
authors.lastname: Umeki
authors.affiliation: Department of Gastrointestinal Oncology, Nagoya Kyoritsu Hospital, Nagoya.
authors.forename: T
authors.initials: T
authors.lastname: Kurimoto
authors.affiliation: Department of Gastroenterology and Oncology, Tokushima University Graduate School, Tokushima.
authors.forename: T
authors.initials: T
authors.lastname: Takayama
authors.affiliation: Department of Medical Oncology, Kochi Health Sciences Center, Kochi.
authors.forename: A
authors.initials: A
authors.lastname: Tsuji
authors.affiliation: Division of Cancer Chemotherapy Center, Osaka Medical College Hospital, Takatsuki.
authors.forename: M
authors.initials: M
authors.lastname: Yoshida
authors.affiliation: Department of Gastroenterology and Hematology, Faculty of Medicine, University of Toyama, Toyama.
authors.forename: A
authors.initials: A
authors.lastname: Hosokawa
authors.affiliation: Department of Chemotherapy, Miyazaki Prefectural Miyazaki Hospital, Miyazaki.
authors.forename: Y
authors.initials: Y
authors.lastname: Shibata
authors.affiliation: Department of Medical Oncology, Toranomon Hospital, Tokyo.
authors.forename: K
authors.initials: K
authors.lastname: Suyama
authors.affiliation: Department of Surgery, Kurashiki Central Hospital, Kurashiki.
authors.forename: M
authors.initials: M
authors.lastname: Okabe
authors.affiliation: Department of gastroenterology, Kushiro City General Hospital, Kushiro.
authors.forename: K
authors.initials: K
authors.lastname: Suzuki
authors.affiliation: Division of Medical Oncology, Department of Internal Medicine, Teikyo University School of Medicine, Tokyo.
authors.forename: N
authors.initials: N
authors.lastname: Seki
authors.affiliation: Department of Gastroenterology, Muroran City General Hospital, Muroran.
authors.forename: K
authors.initials: K
authors.lastname: Kawakami
authors.affiliation: Department of Gastroenterology and Hepatology, Ryuugasaki Saiseikai Hospital, Ryugasaki.
authors.forename: M
authors.initials: M
authors.lastname: Sato
authors.affiliation: Department of Gastroenterology, Hokkaido Cancer Center, Sapporo.
authors.forename: K
authors.initials: K
authors.lastname: Fujikawa
authors.affiliation: Department of Thoracic Malignancy, Osaka Prefectural Medical Center for Respiratory and Allergic Diseases, Habikino.
authors.forename: T
authors.initials: T
authors.lastname: Hirashima
authors.affiliation: Department of Gastroenterology and Metabolism, Nagoya City University Graduate School of Medical Sciences, Nagoya.
authors.forename: T
authors.initials: T
authors.lastname: Shimura
authors.affiliation: Division of Medical Oncology, Shizuoka General Hospital, Shizuoka.
authors.forename: K
authors.initials: K
authors.lastname: Taku
authors.affiliation: Department of Gastroenterology, Dongo Hospital, Yamatotakada.
authors.forename: T
authors.initials: T
authors.lastname: Otsuji
authors.affiliation: Department of Gastroenterology, Kumamoto Regional Medical Center, Kumamoto.
authors.forename: F
authors.initials: F
authors.lastname: Tamura
authors.affiliation: Department of Gastroenterology, Cancer Institute Hospital of JFCR, Tokyo.
authors.forename: E
authors.initials: E
authors.lastname: Shinozaki
authors.affiliation: First Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, Miyazaki.
authors.forename: K
authors.initials: K
authors.lastname: Nakashima
authors.affiliation: Department of Gastroenterology, Saitama Cancer Center, Saitama.
authors.forename: H
authors.initials: H
authors.lastname: Hara
authors.affiliation: Division of Gastrointestinal Oncology, Shizuoka Cancer Center, Shizuoka.
authors.forename: T
authors.initials: T
authors.lastname: Tsushima
authors.affiliation: Center for Advanced Medicine and Clinical Research, Nagoya University Hospital, Nagoya.
authors.forename: M
authors.initials: M
authors.lastname: Ando
authors.affiliation: Department of Biomedical Statistics and Bioinformatics, Kyoto University Graduate School of Medicine, Kyoto, Japan.
authors.forename: S
authors.initials: S
authors.lastname: Morita
authors.affiliation: Department of Clinical Oncology, St Marianna University School of Medicine, Kawasaki.
authors.forename: N
authors.initials: N
authors.lastname: Boku
authors.affiliation: Division of Gastroenterology, University of Tsukuba, Tsukuba.
authors.forename: I
authors.initials: I
authors.lastname: Hyodo
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage* / Q000009:adverse effects; D000068258:Bevacizumab / Q000008:administration & dosage* / Q000009:adverse effects; D002166:Camptothecin / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000473:pathology; D018572:Disease-Free Survival; D064420:Drug-Related Side Effects and Adverse Reactions / Q000145:classification / Q000473:pathology; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage / Q000009:adverse effects; D006801:Humans; D007564:Japan; D053208:Kaplan-Meier Estimate; D002955:Leucovorin / Q000008:administration & dosage / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009944:Organoplatinum Compounds / Q000008:administration & dosage / Q000009:adverse effects; D016016:Proportional Hazards Models; D016896:Treatment Outcome
chemical_list: D009944:Organoplatinum Compounds; D000068258:Bevacizumab; D002955:Leucovorin; D005472:Fluorouracil; D002166:Camptothecin
keywords: bevacizumab; colorectal cancer; irinotecan; oxaliplatin; phase III study